Docetaxel Combined with Thymoquinone Induces Apoptosis in Prostate Cancer Cells via Inhibition of the PI3K/AKT Signaling Pathway

Toxicity and the development of resistance by cancer cells are impediments for docetaxel (DTX), a primary drug for treating prostate cancer (PCa). Since the combination of DTX with natural compounds can increase its effectiveness by reducing its toxic concentrations, we evaluated a combination of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Santosh Kumar, Apata, Tejumola, Gordetsky, Jennifer B., Singh, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770702/
https://www.ncbi.nlm.nih.gov/pubmed/31540423
http://dx.doi.org/10.3390/cancers11091390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770702/
https://www.ncbi.nlm.nih.gov/pubmed/31540423
http://dx.doi.org/10.3390/cancers11091390

Ejemplares similares